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SUMMARY 
Saframycin A，an antitumor antibiotic whose structure is characterized by twin 
heterocyclic quinone skeletons and α-cyanoamine moiety，showed a lethal activity 
against HeLa S3 cells. Prolongation of exposure period from 1 or 2hr to 10 days 
drastically decreased む ugconcentrations required for the same killing effect. Fol-
lowing the i. v. or i. p. administration of [14C]tyrosine-labeled Saframycin A to tumor-
bearing mice，the highest raclioactivity was observed in the small intestine after 15-
30min. Within 1hr，55-78% of the dosed radioactivity was recovered from the urine 
and feces. Radioactivity concentration in the tumor tissue was lower than that in 
the blood. 
E萱ectsof Saframycin A on solid tumors were studied in思 icebearing sarcoma 
180. Saframycin A was administered i. p. from Day 1 through Day 7 and the thera同 
peutic e宜ectwas assessed by the decrease in tumor weight on Day 21 and by body 
weight change between Day 0 and Day 21. Saframycin A produced a marked inhibi-
tion of tumor growth (T/C，54-11 %)， while the e宜ectson body weight were less 
pronounced (TjC，94-43%). 
Di宜e主enttreatment regimens were introduced to tumor-bearing mice from Day 5 
through Day 9 at五xeddoses. Among i. p.， s. c.， and i. v. injections， i.v. injection 
was the most toxic，while continuous i.v. infusion fo主 6hr or for 5 days diminished 
the toxicity to almost the same extent as obtained with s. c. injection. In histological 
examinations，marked necrobiotic changes were noted as early as 2 days after treat-
ment with continuous infusIon. 
Key words: Hete主ocyc1icquinone antibiotic，Saframycin A，solid tumor，sarcoma 180， 
continuous i. v. infusion 
none skeletons andα-cyanoamine moiety at C21 
INTRODUCTION 
position.2-4) The d玄ug undergoes structural 
Saframycin A，an antibiotic isolated from the changes from quinone to hydroquinone，and a-
broth of Streptomyces lavedulae，1) has a struc- cyanoamine toα-carbinolamine after reduction. 
ture characterized by twin heterocyc1ic qui- Both structural changes seem to be required for 
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the e缶 cient binding of the drug to DNA.5) 
When cultu主 edcells are exposed to Saframycin 
A， the synthesis of both hnRNA and pre-rRNA 
is inhibited in preference to D珂 A synthesisの 
Saframycin A has a wide range of antitumor 
activity against Ehrlich ascites carcinoma， leu-
kemia P388， L121O， and B16 melanoma.7) How-
ever， the e査 ectsof Saframycin A on solid tumors 
have not been studied. In this paper， we de-
scribe the cell killing activity against cultured 
耳 eLaS3 cells， together with tissue distribution 
and excretion of Saframycin A determined by 
the use of the antibiotic labeled with [1 4C]tyro-
sine. Based on the pharmacological characteris-
tics， the effects of Saframycin A on sarcoma 180 
in solid form in relation to di百 erenttreatment 
regimens involving continuous i. v. infusion 
were studied. 
MATERIALS AND躍 ETHODS 
Cell killing effect of Safr.αη 'zyan A: 
HeLa S3 cells were grown in monolayer cul-
tures in Eagle' minimal essential medium sup-
plemented with 10% fetal bovine se主 um. In-
cubations were conducted at 370C in a humidified 
atmosphere of 5 % C02. For study on pulse 
exposure， cells were plated in appropriate num-
bers， exposed to Saframycin A at di宜 erentcon-
centrations for 1 or 2hr， and washed 3 times 
with the medium. After incubation for 10 days， 
colonies formed were stained with 0.25弘 crystal 
violet and counted. For study on long term 
exposure， cells were continuously exposed to 
Saframycin A for 10 days. 
Distγibution an品 α cretionof Sajiγα:mycin A 二 
Saframycin A was biosynthetically labeled with 
L伊 C(U)]tyrosine(New England Nuclear)， and 
pu主 i五 edby silica gel thin layer and column chro-
matography as previously described.1) Saframy-
cin A thus purified had a specific activity of 
0.38Cifmol. After i. v. or i. p. administration 
of (14C]Saframycin A to mice bea主 ingsarco血 a 
180， the mice were killed at various periods of 
time and the organs were dissected. Specimens 
collected were the blood， liver， spleen，kidneys， 
small intestine， lung， brain，gall bladder， thymus， 
lymph nodes，urine，and feces. Specimens weigh-
ing 150-500 mg were combusted with a co現 bus-
tion aid (Packard) using a sample oxidizer 
(Packard， Model 306).τhe radioactivity recove-
red in 6 ml Carbosorb (Packard) and. 13 ml Perma-
fluor (Packard) was measured with a liquid scin-
tillation counter. 
Tumor: 
Sarcoma工 80 was maintained in the ascites 
form in ICR mice (CLEA Japan Inc.) by weekly 
i. p. transplantations of ascites in a volume of 
0.05m l. For the propagation of solid tumors， 
the same volume of ascites was inoculated s. c. 
in the inguinal region of ICま miceweighing 
18-20g. 
Continuous infusion : 
The continuous i. v. infusion of mice was car-
ried out as described by Grindey et a1. 8) Brie丑 y， 
a lateral tail vein was punctured with a 27・ gauge 
needle. After the needle was withdrawn， the 
vein was cannulated with a polyethylene tubing 
(Intramedic， PE1O) to a depth of about 2.5 cm. 
The other end of the cannula was connected to 
a plastic disposable syringe which was placed 
on a Harvard infusion pump (Medel 975). Dur-
ing the experiment， the mice were administered 
food and water ad libitum. 
RESULTS AND DISCむ SSION 
Cell killing activity of Saframycin A: 
司直 enHeLa S3 cells were exposed to Safra-
mycin A， it exerted a direct cytotoxicity. 
G主 owthinhibition was detected at a concentra-
tion as low as 0.02μgJml (data not shown).τhe 
lethal activity of Saframycin A was assessed by 
the colony forming abili ty of the cells exposed 
to the d主 ug. As shown in Fig. 1 (A)， the su主 vival 
response of HaLa Ss. cells following a 1 or 2 hr 
contact period was biphasic， i.e.， cells tended 
to be more sensitive at concentrations higher 
than 2.0 or 1. 0μg/ml， respectively， whe主 easa 
shoulder was observed in response to continuous 
exposure (Fig. 1 (B)). The concentration of 
Saframycin A required for the same killing 
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Fig. 1. E宜 ectof pulse (left) or long ter民 (right)exposure of Safrarnycin A on survival of 
HeLa 53 cells. 
Cells were treated with Safrarnycin A for 1 hr or 2 hr，and then incubated for 10 days 
to deterrnine the colony forrning ability (pulse exposure). Cells were continuously 
exposed for 10 days until colonies were counted (long terrn exposure). 
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Fig.2. Tissue distribution after i. v. (1eft) or i. p. (right) adrninistration of [14C]Safrrnycin A 
to turnor-bearing rnice. 

(14C]Safrarnycin A (0.38 Cifrnol) was i. v. or i. p. adrninistered at a dose of 0.5 or 

0.9rng/kg， respectively. Values are expressed as aμg equivalent of Safrarnycin A. 
Data are averages of three rnice. 
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e査 ectwas 500 times less with continuous ex-
posure than short time exposure. 

Metabolic fate of SafiγaycinA: 
悦 
In an attempt to provide a pharmacological 
basis for the antitumor action of Saframycin A， 
distribution of the d主 uglabeled with (14C]tyrosine 
was .measured in tissues of tumor七 ea主 ingmice 
after i. v. or i. p. administration (Fig. 2). High 
initial concentrations were observed in the smal1 
intestine，kidneys，and 1iver. Concentrations in 
the liver and kidneys fel1 0茸 rapidlyfollowed 
by a steep rise in the small intestine. Moderate 
initial concentrations were obtained in the lung 
and spleen，while radioactivity was not detected 
in the thymus，lymph nodes，bone marrow， and 
brain (data not shown). Three hours after in-
jection， radioactivity was not detectable in any 
tissue. Virtually the same resu1ts were obtained 
with i. v. and i. p. administrations. Radioac-
tivity concentration in the blood decreased rapid-
ly with a half-life of 4.5 min with i. v. injection. 
Lower concentrations were detected in tumor 
tissues than in the blood. 
After i. v. administration of (14C]Saframycin A 
to mice， 78% of the dosed radioactivity 寺vas 
excreted within 1 hr. More radioactivity ap-
peared in the urine (46 %) than in feces (32 %) 
(Table 1). A few per cent of the total dosage 
Table 1. Urinary and fecal excretion of 
Saframycin A 
e
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d
fecal radioactivity were indicative of hepato-
biliary excretion of Saframycin A. The ap-
parently weak tissue圃 bindingand rapid excre-
tion are characteristic of the metabolic fate of 
saframycin A. 
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The initial experiments were carried out to 
test the activity of Saframycin A against sarcoma 
180. Mice were injected daily with varying 
doses of Saframycin A by i. p. route for 7 days. 
starting day 1 after the 加盟 ortransplantation. 
A signi五cantretardation of tumor growth rang-
ing from 54 to 11 % of the con trol val ue was 
observed as the doses of Saframycin A were 
increased (Table 2). During the same period， 
Saframycin A-treated mice gained less in body 
weight which ranged from 94 to 43% of the. 
control value. T/C (Treated over Control) of 
tumor weight was about 20-49% lower than 
that of body weight change， suggesting a selec-
tive toxicity of Saframycin A against tu立lOr 
cel1s. Lethal toxicity was demonstrated in the 
animals treated with higher doses of the drug. 
The e茸 ectivenessof Saframycin A was compa-
rable to that obtained with Mitomycin C in-
jected at a dose of 1 mg/kg. On the other hand， 
injection of Saframycin A every othe主 daywith 
the same total doses as for daily injection was. 
less effective. 
Effects of different tγeat悦郎tγ -egi悦 enson the' 
&混乱ぬ悦0γ activityof Saframycin A : 
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ments， treatment was delaye長 until 5 days after 
the tumor implantation. The tumor was of a 
be different from that of an already established 
tumor.の	 Therefore， in the following experi-
吐 
23 
palpable size (100-150mm3) at this stage. Vari-
[UC]Saframycin A was injected at the same 
dose as in Fig. 2. 1ミadioactivityrecovered from 
urine and feces is expressed as per cent of do-
sage. Values are the average of three mice. 
was found in the gal1 bladder (data not shown). 
This fact as well as relatively high levels of 
ous routes of injection were compared using a 
五xedtotal dose. Of these with a single dose， 
i. v. injection was the most toxic， i.e.， the in-
jection at a dose of 1.25 mg/kg (1/2.6 LD50) pro-
duced 100 % mortality，followed by s. c. and i. v. 
administrations (Table 3). In al cases， the: 
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Table 2. Effect of i.p. administration of Saframycin A on sarcoma 180 in solid form 
τD λu
A
/l -J
J、 
-1jl
汁 
一 フ  
ノ、ノ¥ノ 
1j¥jl
ノ 、  
、 、j1
ノーノ〕〆
、
04678352083
f f
ft
∞ ]
 ， .VT t¥c τ h urt-09266494085
-phah
4.1L11pti1
川 ソ
が五一 
f¥/i
五一
、  
一
/i 1
5
68271587
弘之 
fl
市山℃一山
、ノ 
れ 
/I
、 
、‘
一
 
ょ 
A v rA vr tumor weightC) V〆 a ng戸』  Treatment 説。主 talitT) 
g士 SE(T/C，弘〉 g
一 
none 4.5土 0.5(100) 
saframycin A， 0.25mg/Kg， qd 1-7a) 2.4土1.5(54) 
0.50mg/Kg，qd 1-7 1.4士 0.8(31) 
0.75mg/Kg， qd 1-7 2.0土1.3(46) 1/6 
1.0 mg/Kg，qd 1-7 0.9土 0.7(20) 
1. 25mg/Kg， qd 1-7 0.5:t0.2( 11) 工/6
5・ FU 25.0 mg/Kg， qd 1.7 1.2土 0.5(28) 1i 、 、
mitomycin， C， 1.0mg/Kg，qd 1-7 0.7土 0.3(16) 
none 4.0:t1. 3(100) 
saframycin A， 0.50mg/Kg， q2d 1-13め 3.6土1. 6(89) 
1.0 mg/Kg， q2d 1-13 3.5土1.6(87)
ιι14.
工/6 
a) Drug gi ven daily from Day 1 through Day 7. 
め Druggiven every other day from Day 1 through Day 13. 
C) Tumpr weight was measured on Day 21. 
め (Averagebody weight on Day 21 in which tumor weight was excluded)-(A verage body weight oIi 
Day 0) 
e) Mice died of toxicity before Day 21. 
Table 3. Varying of routes of administration and e:ficiency of Saframycin A 
against sa主 coma180 in solid form 
A vr tumor weight A vr body weight change Treatment Mortality 
g:tSE (T/C，弘) g (T/C， %) 
none 4.6士1.2(100) 14.0(100) 
i.p.， 0.75mg/Kg， qd 5-9a) 2・9土1.8( 63) 10.2( 73) 
i.p.， 1.25mg/Kg， qd 5-9 1.9土 0.4( 40) 6.0( 43) 1/4 
s.c.， 0.75mg/Kg， qd 5-9 1. 6:t0.5( 34) 5.5( 39) 
S心， 1.25mg/Kg， qd 5-9 1. 1土 0.6( 23) 3.5( 25) 
i.v.， 0.75mg/Kg， qd 5-9 0.3土 0.2( 6) 1.4( 10) 
i.v.， 1.25mg/Kg， qd 5-9 4/4 
i.v.， for 6 hr，b) 
0.75mg(Kg， qd 5-9 1.5:t1.7( 33) 3.2( 23) 
1.25mg/Kg， qd 5-9 0.6土 0.3( 12) 2.0( 14) 
i.v.， for 5 days，c) 
0.75mg(Kg， Day 5・Day 10 1.4:t1.2( 31) 5.4( 39) 
a) Saframycin A given daily from Day 5 through 9 Day 9. 
b) Saframycin A was continuously infused for 6 hr/day at a rate of 0.15 m l/hr from Day 5 through 
Day 9. 
c) Saframycin Awas continuously infused for 5 days at a rate of 1.0 ml/day. 
effects of Saframycin A on both body weight the i. v. route is used almost exclusively. Based 
and tumor weight were comparable to each other. on the facts that Saframycin A has a short half-
Selective toxicity against tumo工 cel1s decreased life in the blood followed by a rapid urinary 
when the initiation of treatment was delayed. excretion and that it is very e宜 ective for cell 
In the clinical use of antineoplastic agents， killing in a culture by long incubation at low 
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Fig. 3. Non-treated sarcoma 180 eight days after implantation. (A) Proliferation of tumor cells 

and their invasion to the soft tissue are signi五 cant and accompanied with extensive 

命
necrosis. H. E. X 40 (召) The cells reveal a bizzar appearence and a hyperchromatic 
nucleus with prominent nucleoli. H. E. X 100 
Fig. 4. Sarcoma 180 two days after the treatment of Saframycin A by continuous i. v. infusion 

for 6 hr at a dose of 0.75 mg/kg. (A) Tumor size decreased with areas of necrosis. H. E. 

X 40 (B) H. E. x 200 (C) Necrobiotic appearence with a number of cell debris. H. E. 

x400 

drug concentrations， continuous I. v. infusion of 6 hr/day， or for 5 days produced less toxicity 
Saframycin A was studied as a modi五 cationof than a single i. v. push (Table 3)， I. e.， the 
i. v. injection. 1t was found that infusion for toxicity decreased to a si限 ilarlevel as obtained 
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with s. c. injection. Histological examinations 
revealed that a marked degeneration of tumor 
tissues was caused at the early phase of treat-
ment by continuous i. v. infusion (Fig. 3 and 4). 
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まとめ
キノン型制癌抗生実物サフラマイシンA の HeLa締
臨に対する殺細胞作用は接触時間を延長することにより
著しく増強した。異項環母揺を 14C-チロジンで生合成的
にラベルしたサフラマイシンAを担ガンマウスに静聴内
投与すると，車中半減携は 4.5分と短く，放射活d注は
投与後 15，.30分で十二指腸で最大に達し， 1時間以内
に投与量の 78%が尿及び糞寵から回収された。これら
薬理的脅長を踏えてサフラマイシンAの匡型癌に対する
効果を，サノレコーマ工80の皮下移植系を用いて検討し
た。 0.25，..1.25mg/kg/dayの範囲のサフラマイシンAを
題虜移植後第 1日自から 7日間マウスに腹控内投与し， 
21日自に全マウスを屠殺して期定した麗療重量は，対照
群の54，..11誌に減少した。サフラマイシンAは同時にマ
ウスの体重増加にも影響を与えたが，その影響は対東群
の94，.43%に止予サフラマイシンAの腫蕩に対する選
択毒性が窺えた。上記の薬理的砦長から，サフラマイシ
ンAの至遥投与法として尾静脈内持続注入が考えられ
た。この投与法により，間歎投与法に比較し毒性の減少
をみることができ，産量識学的に早期に麗蕩の壊死橡を認
めた。 
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